Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

PD-L1 amplification

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

PD-L1 amplification	Gastric Cancer	PD-L1 amplification	Gastric Cancer	tremelimumab-actl Sensitive: C2 – Inclusion Criteria tremelimumab-actl Sensitive : C2	tremelimumab-actl Sensitive: C2 – Inclusion Criteria tremelimumab-actl Sensitive : C2
PD-L1 amplification	Gastric Cancer	PD-L1 amplification	Gastric Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
PD-L1 amplification	Non Small Cell Lung Cancer	PD-L1 amplification	Non Small Cell Lung Cancer	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
PD-L1 amplification	Triple Negative Breast Cancer	PD-L1 amplification	Triple Negative Breast Cancer	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3
PD-L1 amplification	Diffuse Large B Cell Lymphoma	PD-L1 amplification	Diffuse Large B Cell Lymphoma	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3
PD-L1 amplification	Cervical Cancer	PD-L1 amplification	Cervical Cancer	nivolumab Resistant: C4 – Case Studies nivolumab Resistant : C4	nivolumab Resistant: C4 – Case Studies nivolumab Resistant : C4